Loading clinical trials...

Predictability of OSA With a Subjective Screening Scale (OSASSS1) | Clinical Trials | Clareo Health

COMPLETED

Predictability of OSA With a Subjective Screening Scale (OSASSS1)

Predictive Value of OSA Based on the Evaluation of the Subjective Feeling of the Air Flow Through Airways, a Randomized Controlled Study

NCT06092710•Center for Sleep Medicine - Clinique André Renard

View on ClinicalTrials.gov

Summary

the study aims to evaluate the accuracy correlation between subjective perception of the air flow through airways from patients and survey and/or polysomnography they spent, using a brief clinical protocol they answered with a manual therapist

Detailed Description

The subjects in the study are 18 to 77 years old and present the following conditions: * polysomnography and sleep survey realized at the Center for Sleep Medicine André RENARD, without any informations of the results for the experience group * sleep survey with no sleep trouble found for the control group

Eligibility

Age

18 - 77 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Female or male subjects aged 18 to 77 years old
•subjects who have performed a PSG at the sleep medicine center André Renard for the study group
•subjects with no sleep disorder on sleep survey for the control group
•Subjects who agree to comply with the requirements of the study.
•Subjects who are of age (and know how to read and write) who have given their informed, explicit consent in advance to any procedure related to the trial, the study or the investigation conducted on human beings, with the objective of developing knowledge specific to the exercise of health care professions, as set out in Royal Decree No. 78 of 10 November 1967 on the practice of the health care professions (Act of 27 December 2005)

Exclusion Criteria

•subjects with acute infections
•subjects with trauma within the last 72 hours
•subjects who already benefit from OSA treatment
•subjects with known perceptual disorders, for example post-stroke
•subjects with current or recent chemotherapy and radiotherapy treatment
•Pregnant women
•Criteria related to prior or concurrent treatments:
•Treatment with antipsychotics, anxiolytics, soporifics or muscle relaxants started within the two months preceding the study.
•Treatment with intraoral implants during the study or in the two months preceding the study

Locations (1)

Centre de médecine du sommeil- Clinique André Renard

Herstal, Liège, Belgium

Key Dates

Start Date

January 1, 2023

Primary Completion Date

June 19, 2024

Completion Date

November 30, 2024

Last Updated

June 3, 2025

Enrollment

112

ACTUAL participants

Conditions

Obstructive Sleep ApneaOSA

Interventions

neuro-sensorial subjective evaluation of the airways collapsibility

DIAGNOSTIC_TEST

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Predictability of OSA With a Subjective Screening Scale (OSASSS1)

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

Cognitive Evaluation of Patients With Eating Disorders

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa